Pfizer's Pain Pipeline No Sore Spot: Firm Pursues Novel Targets, New Markets
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer's investment in pain R&D is aimed at capturing two of the most significant advantages in the pharmaceutical industry: unmet medical need and innovative drug targets. With a track record in the field and over 80 percent of its pain pipeline hitting novel targets, Pfizer should be well-situated to capitalize on that opportunity.
You may also be interested in...
Pfizer cuts 800 R&D jobs
With its Lipitor exclusivity cliff looming in 2011, Pfizer is making more staff cuts, laying off 800 research and development employees (roughly 5 to 8 percent of its global research staff) in addition to the corporate-wide 13,500 jobs and eight plants it has shed over the past two years. The move, announced Jan. 13 at the JPMorgan Healthcare Conference in San Francisco, follows an extensive reorganization of the firm's research program that Pfizer made public last September. The firm has abandoned R&D in heart disease, anemia, osteoarthritis and obesity to focus on other areas, like Alzheimer's, cancer and pain/inflammation (1Pharmaceutical Approvals Monthly November 2008, p. 10). Pfizer expects to have 24-28 Phase III studies by year-end, split evenly between new molecular entities and new indications. That's up from eight such studies in January 2007
Savient Seeks FDA Priority Review For Puricase
Savient is seeking a six-month priority review from FDA for its gout drug pegloticase (formerly Puricase), setting it up for an action date in late April if granted. The BLA, submitted Oct. 31, could face tough safety scrutiny at FDA, however, on cardiovascular events
Pfizer’s Tanezumab For Pain Turns Heads At Rheumatology Meeting
Firm looking at 2011-2012 filing for drug candidate, now in Phase III.